LAUSR

Despite the reported role of poly(ADP‐ribose) polymerase (PARP) in asthma inflammation, its contribution during remodeling is not clearly known. The main aim of the current investigation was to examine the potential of olaparib, a pharmacological inhibitor of PARP against airway remodeling using an ovalbumin (OVA)‐based murine model of chronic asthma. The results demonstrated that post‐challenge olaparib treatment (5 mg/kg i.p., 30 min after OVA exposure) for six weeks (3 days/week) attenuates inflammation, mucus production, and collagen deposition in lungs. Additionally, olaparib blunted the protein expression of STAT‐6 and GATA‐3 considerably along with a modest reduction in p65‐NF‐κB phosphorylation. Furthermore, olaparib normalized the OVA‐induced redox imbalance as reflected by data on reactive oxygen species, malondialdehyde, protein carbonyls, and reduced glutathione/oxidized glutathione ratio. Interestingly, the protection offered by olaparib was further linked with the altered level of NLRP3 inflammasome‐mediated IL‐1β release and consequent expression of its downstream targets matrix metalloproteinase‐9 and transforming growth factor beta. Suppressed collagen deposition in the lungs correlates well with the reduced expression of vimentin upon olaparib treatment. Finally, olaparib restored the expression of histone deacetylase 2, a steroid‐responsive element in asthma. Overall, results suggest that olaparib prevents OVA‐induced airway inflammation as well as remodeling via modulating inflammasome signaling in mice. © 2019 IUBMB Life, 1–11, 2019